Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Review IDs Dietary Factors Linked to Lower CRC Incidence
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Decreased colorectal cancer (CRC) incidence is seen in association with use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), magnesium, folate, and high consumption of fruits and vegetables, fiber, and dairy products, according to an umbrella review published online Sept. 28 in Gut.
U.S. Government to Ship Millions of Rapid COVID-19 Tests This Week
TUESDAY, Sept. 29, 2020 (HealthDay News) — The U.S. government will start distributing millions of rapid COVID-19 tests to states this week with the goal of reopening schools.
Global Death Toll From COVID-19 Passes 1 Million
TUESDAY, Sept. 29, 2020 (HealthDay News) — The global COVID-19 pandemic reached a grim new milestone on Tuesday: 1 million dead.
AP News Article
Johns Hopkins University
Gabapentin Does Not Lower Pain Scores in Chronic Pelvic Pain
TUESDAY, Sept. 29, 2020 (HealthDay News) — For women with chronic pelvic pain, gabapentin treatment does not result in significantly lower pain scores and is associated with more side effects than placebo, according to a study published online Sept. 26 in The Lancet.
Proton Pump Inhibitor Use Linked to Increased T2DM Risk
TUESDAY, Sept. 29, 2020 (HealthDay News) — Regular use of proton pump inhibitors (PPIs) is associated with an increased risk for type 2 diabetes, according to a study published online Sept. 28 in Gut.
Lockdown Tied to Worsening of Musculoskeletal Conditions
TUESDAY, Sept. 29, 2020 (HealthDay News) — Early stages of the U.K. COVID-19 lockdown had negative consequences for people with musculoskeletal conditions, according to a letter to the editor published online Sept. 22 in Rheumatology: Advances in Practice.
Abstract/Full Text (subscription or payment may be required)
New FDA Applications for Opioids Often Based on Short Trials
TUESDAY, Sept. 29, 2020 (HealthDay News) — New drug applications (NDAs) for prescription opioids for pain have been based on pivotal trials of short or intermediate duration, often in narrowly defined pain populations, according to a study published online Sept. 29 in the Annals of Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
Hydroxychloroquine Tied to Heart Problems Prior to Pandemic
MONDAY, Sept. 28, 2020 (HealthDay News) — Real-world, pre-COVID-19 adverse events data show hydroxychloroquine (HCQ) and chloroquine (CQ) are associated with cardiovascular adverse events (CVAEs), according to a study published online Sept. 22 in the British Journal of Clinical Pharmacology.
Only Two-Thirds of Parents Planning to Get Flu Shots for Their Children
MONDAY, Sept. 28, 2020 (HealthDay News) — One-third of parents say they will forgo the flu vaccination for their children this year, despite public health recommendations, according to the C.S. Mott Children’s Hospital National Poll on Children’s Health.
Clinical Severity Lower With Vitamin D Sufficiency in COVID-19
MONDAY, Sept. 28, 2020 (HealthDay News) — Vitamin D sufficiency is associated with reduced clinical severity, inpatient mortality, and serum levels of C-reactive protein (CRP) among patients infected with COVID-19, according to a study published online Sept. 25 in PLOS ONE.
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Sept. 21 to 25, 2020. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
ACIP Provides Recommendations on Meningococcal Vaccination
FRIDAY, Sept. 25, 2020 (HealthDay News) — Routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended for adolescents aged 11 to 12 years with a booster at age 16 years, according to a report published in the Sept. 24 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
United First U.S. Airline to Offer COVID-19 Testing for Passengers
THURSDAY, Sept. 24, 2020 (HealthDay News) — The first COVID-19 testing program for airline passengers in the United States will be introduced Oct. 15 by United Airlines.
Chinese Company Says Its COVID-19 Vaccine Should Be Available in U.S. in Early 2021
THURSDAY, Sept. 24, 2020 (HealthDay News) — A Chinese pharmaceutical company claims its COVID-19 vaccine should available by early next year for distribution in the United States and other countries.
Survey: Rheumatic Diseases Pose Routine Challenges
THURSDAY, Sept. 24, 2020 (HealthDay News) — Many patients with rheumatic diseases face significant challenges in their daily lives, including affordability issues, lifestyle and activity limitations, and negative effects on mental and emotional health, according to the results of a survey released by the American College of Rheumatology (ACR).
Cognition-Enhancing Supplements May Contain Unapproved Drugs
THURSDAY, Sept. 24, 2020 (HealthDay News) — Supplements marketed to improve memory and cognitive function frequently contain unapproved drugs, often at supratherapeutic dosages, according to a study published online Sept. 23 in Neurology: Clinical Practice.
Abstract/Full Text (subscription or payment may be required)
Guidelines Updated for Managing Dyslipidemia to Cut CVD Risk
THURSDAY, Sept. 24, 2020 (HealthDay News) — In a synopsis of the 2020 updated clinical practice guideline from the U.S. Department of Veterans Affairs and the U.S. Department of Defense, published online Sept. 22 in the Annals of Internal Medicine, recommendations are presented for the management of dyslipidemia to reduce cardiovascular disease (CVD) risk.
Clinical Practice Guideline Synopsis
Evidence Review (subscription or payment may be required)
Editorial (subscription or payment may be required)
FDA Requiring Labeling Changes to Benzodiazepine Prescribing Information
THURSDAY, Sept. 24, 2020 (HealthDay News) — In response to reports of misuse and abuse of benzodiazepines, the U.S. Food and Drug Administration is now requiring class-wide labeling changes to the prescribing information, the agency announced yesterday.
Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
THURSDAY, Sept. 24, 2020 (HealthDay News) — For individuals with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors are associated with a reduced risk for cardiovascular events during short-term follow-up, according to a study published online Sept. 23 in The BMJ.
Teens’ Mental Illness Treatment May Not Follow Guidelines
THURSDAY, Sept. 24, 2020 (HealthDay News) — There is great variation in the treatment of mental illness in adolescents, according to a study published online Sept. 21 in the Proceedings of the National Academy of Sciences.
As Flu Season Approaches, Clinicians Brace for Potential ‘Twindemic’
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Flu shots may be more important than ever this year, as COVID-19 presents new challenges for clinicians and communities this flu season. HD Live! spoke with Nadia Eltaki, M.D., director of clinical operations at Sibley Memorial Hospital in Washington, D.C., to discuss how clinicians can potentially lessen the potential for an overlapping superinfection, or “twindemic.”
U.S. COVID-19 Death Toll Hits 200,000 as Cases Climb in 22 States
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — The U.S. COVID-19 death toll reached the tragic milestone of 200,000 on Tuesday, with at least 22 states now reporting a rise in new cases. Just last Monday, only nine states were reporting increases in new COVID-19 cases, CNN reported. For the most part, the case spikes are showing up in the country’s heartland and the Midwest.
J&J COVID-19 Vaccine Begins Final Stage of Clinical Trials
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — The final stage of clinical trials for Johnson & Johnson’s COVID-19 vaccine have started, the company announced Tuesday.
Stricter Vaccine Approval Rules Coming From FDA
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Stricter guidelines for emergency use authorization of a vaccine against the new coronavirus could soon be issued by the U.S. Food and Drug Administration.
Metformin May Slow Cognitive Decline in Seniors With T2DM
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — For older adults with type 2 diabetes, cognitive decline is slower and dementia risk reduced for those receiving metformin, according to a study published online Sept. 23 in Diabetes Care.
Abstract/Full Text (subscription or payment may be required)
CDC: Women More Likely to Experience Anxiety, Depression
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Women are more likely to experience anxiety and depression, and women and older children are more likely to receive mental health treatment, according to new statistics from four data briefs published by the U.S. Centers for Disease Control and Prevention National Center for Health Statistics.
Abstract/Full Text – Terlizzi and Villarroel
Abstract/Full Text – Villarroel and Terlizzi
Abstract/Full Text – Terlizzi and Zablotsky
Abstract/Full Text – Zablotsky and Terlizzi
Oral Steroids May Raise Risks for Diabetes, HTN, VTE in Children
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Children with current glucocorticoid exposure have increased risks for diabetes mellitus, hypertension, and venous thromboembolism (VTE), according to a study published online Sept. 9 in the American Journal of Epidemiology.
Abstract/Full Text (subscription or payment may be required)
Rates of COVID-19 Infection Higher in Blacks, Hispanics
TUESDAY, Sept. 22, 2020 (HealthDay News) — Black and Hispanic individuals are experiencing an excess burden of severe acute respiratory syndrome coronavirus 2 infection, according to a study published online Sept. 22 in PLOS Medicine.
Perrigo Asthma Inhalers Recalled Due to Clog Risk
TUESDAY, Sept. 22, 2020 (HealthDay News) — Perrigo inhalers have been recalled because they could clog and not provide patients with any or enough medication, the U.S. Food and Drug Administration says.
PrEP Prescribing Low in the U.S., Even Among HIV Care Providers
TUESDAY, Sept. 22, 2020 (HealthDay News) — Even among HIV-focused practitioners, preexposure prophylaxis (PrEP) prescribing is not routine, according to a study published online Sept. 3 in PLOS ONE.
Glucocorticoids Linked to Hospitalized Infection Risk in RA
TUESDAY, Sept. 22, 2020 (HealthDay News) — For patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drug (DMARD) therapy, continued use of glucocorticoids is associated with an increased risk for hospitalized infections, according to a study published online Sept. 22 in the Annals of Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
COVID-19 Death Toll Nears 200,000 in the United States
MONDAY, Sept. 21, 2020 (HealthDay News) — As the U.S. COVID-19 case count neared 200,000 on Monday, public health experts debated whether the spread of the virus will continue to slow or a new surge will come, as cold weather returns to much of the country.
AstraZeneca Releases COVID-19 Vaccine Trial Plans
MONDAY, Sept. 21, 2020 (HealthDay News) — AstraZeneca is the latest drug company to release details about human tests of its COVID-19 vaccine in response to public demand for such information. Americans have increasing doubts about a COVID-19 vaccine, and experts are worried that an unproven or unsafe vaccine may be released prematurely due to pressure from President Donald Trump, The New York Times reported.
Botox for TMJ Disorder Does Not Affect Jaw Bone Density
FRIDAY, Sept. 18, 2020 (HealthDay News) — Jaw bone density and volume are similar between women who had botulinum toxin (BTX) injections to treat temporomandibular muscle and joint disorders (TMJDs) and those who did not, according to a small study published online Sept. 3 in the Journal of Oral Rehabilitation.
Abstract/Full Text (subscription or payment may be required)
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Sept. 14 to 18, 2020. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Read Full Article
Details Emerge on Unexplained Illness in AstraZeneca COVID-19 Vaccine Trial
FRIDAY, Sept. 18, 2020 (HealthDay News) — New details surfaced on Thursday on an unexplained neurological condition that struck a volunteer who was participating in AstraZeneca’s COVID-19 vaccine trial.
Drug May Reduce Need for Ventilators in COVID-19 Patients
FRIDAY, Sept. 18, 2020 (HealthDay News) — An inflammation-fighting medicine was associated with reduced use of ventilators among COVID-19 patients, according to a study that included mainly Hispanics and Blacks.
Depression Common Among Psoriasis Patients
Homicide, Suicide, and Overdose Leading Causes of Maternal Death 
Model Predicts Poor Outcomes Within 30 Days of a Before Medically Advised Discharge 
Fewer Than Half of Drug Overdose Survivors Go to the Hospital 
2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults 
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus 
.jpg)
